Liu, M., Zhang, L., Huang, Q., Li, N., Zheng, B., & Cai, H. (2019). Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer. Cancer Manag Res.
Stile di citazione ChicagoLiu, Maobai, Longfeng Zhang, Qishu Huang, Na Li, Bin Zheng, e Hongfu Cai. "Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer." Cancer Manag Res 2019.
Citazione MLALiu, Maobai, et al. "Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer." Cancer Manag Res 2019.